Cancer is a battle that has seen its fair share of setbacks, but today, we bring you a ray of hope amidst the struggle. In a world where cancer rates seem to be rising, especially among the young, and where modern life's hazards, from microplastics to air pollution, pose potential risks, a glimmer of optimism emerges from the American Cancer Society's latest report.
The report, published this week, reveals a stunning victory: 70% of cancer patients diagnosed between 2015 and 2021 survived for at least five years. This is a remarkable improvement from the mid-1970s, when the survival rate was a mere 49%.
"This is a testament to the power of research and innovation," says Rebecca Siegel, lead author and senior scientific director of cancer surveillance research at ACS. "We've turned many cancers, once considered a death sentence, into chronic diseases."
Even the most aggressive cancers are now more survivable. Siegel's team analyzed data from cancer registries and the National Center for Health Statistics, and their findings are encouraging. For instance, the five-year survival rate for myeloma has jumped from 32% to an impressive 62%, while liver cancer and lung cancer have seen similar gains, from 7% to 22% and 15% to 28%, respectively.
But here's where it gets controversial: while survival rates are improving, marginalized communities still face a higher risk of cancer mortality. Native American people, for example, have double the death rates for kidney, liver, stomach, and uterine cervix cancers compared to white people.
"Lack of access to quality care and socioeconomic factors continue to drive racial disparities," explains Ahmedin Jemal, senior vice president of cancer surveillance, prevention, and health services research at ACS. "We need to focus our efforts on these areas to ensure that successful cancer control interventions are accessible to all."
Despite these gains, the battle against cancer is far from over. The report estimates that over 2 million new cancer cases will be diagnosed in 2026, and more than 600,000 lives will be lost to the disease.
And this is the part most people miss: the incidence of many common cancers is rising, including breast, prostate, oral, pancreas, and endometrial cancers. At the same time, political decisions, like the Trump administration's funding and staff cuts across research institutions, threaten to undo the progress made in reducing cancer deaths.
"The federal government has been a key funder of cancer research, leading to longer lives for those with fatal cancers," says Shane Jacobson, CEO of ACS and its Cancer Action Network. "But now, with funding cuts and potential impacts on health insurance access, we risk reversing this progress and stalling future breakthroughs."
So, what's the big takeaway? Investment in cancer research saves lives. The survival gains we've seen over the past five decades are a direct result of our commitment to research and innovation. The question now is: will policymakers continue to support these investments, or will they undermine the progress we've made?
It's a critical juncture in the fight against cancer, and the choices made today will shape the future of cancer survival for generations to come.
